[{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Neostigmine Methylsulfate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Ammonium, (m-hydroxyphenyl)trimethyl-, methyl sulfate, dimethylcarbamate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S for Neuromuscular blockade.

                          Brand Name : Prevduo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 12, 2023

                          Lead Product(s) : Neostigmine Methylsulfate,Glycopyrronium Bromide

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.

                          Brand Name : Bloxiverz

                          Molecule Type : Small molecule

                          Upfront Cash : $14.5 million

                          July 01, 2020

                          Lead Product(s) : Neostigmine Methylsulfate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Exela Pharma Sciences, LLC.

                          Deal Size : $42.0 million

                          Deal Type : Divestment

                          blank